The table below shows 4D Molecular Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$109.08M
-$134.59M
-$75.79M
-$86.69M
-$69.13M
-$50.91M
Capital expenditure
$536.00K
$3.79M
$2.77M
$11.54M
$9.11M
$1.00M
Investing cash flow
-$92.97M
-$302.44M
$115.72M
-$17.05M
-$172.68M
-$1.00M
Dividends paid
-
-
-
-
FDMT operating cash flow (10-K history)
4D Molecular Therapeutics, Inc. reported operating cash flow of -$109.08M for fiscal year 2025. That is up 18.9% from -$134.59M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$36.71M (FY 2019) to -$109.08M. Figures come from the company's audited annual reports as filed with the SEC.